||Tom joined MedEquity Capital as a Vice President in 2016 and his primary responsibilities include helping to acquire and operate MedEquity’s portfolio companies. |
Prior to MedEquity, Tom worked in both corporate and advisory arenas, most recently at Vertex Pharmaceuticals. Vertex is a Boston-based biotechnology firm which develops and commercializes novel drug therapies, most notably those for the treatment of Cystic Fibrosis. At Vertex, Tom managed all financial and valuation exercises used by senior leadership for optimal decisions on mergers and acquisitions, licensing and strategic initiatives. In addition to Cystic Fibrosis, Tom evaluated opportunities within HCV, autoimmune diseases and influenza. Prior to Vertex, Tom was a valuation consultant at Duff & Phelps, where he managed client engagements for strategic, financial and tax purposes across a myriad of industry verticals.
Tom has a degree in Finance from Boston College (Magna Cum Laude) and an MBA from the Harvard Business School. He is also a Chartered Financial Analyst (CFA) and a member of both the CFA Institute and CFA Society Boston. When not at work, he enjoys golfing his way around Massachusetts, being bossed around by his energetic dog, Newman, and watching Tom Brady and the Patriots win football games.